Scarica l'app Stockscreener
141.20
2.37%
3.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$137.93
Aprire:
$138.75
Volume 24 ore:
1.15M
Relative Volume:
1.10
Capitalizzazione di mercato:
$14.08B
Reddito:
$2.68B
Utile/perdita netta:
$428.00M
Rapporto P/E:
33.72
EPS:
4.1873
Flusso di cassa netto:
$593.10M
1 W Prestazione:
+3.78%
1M Prestazione:
+2.80%
6M Prestazione:
+9.94%
1 anno Prestazione:
-6.19%
Intervallo 1D:
$138.27
$142.15
Intervallo di 1 settimana:
$135.00
$142.15
Portata 52W:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
141.20 | 13.75B | 2.68B | 428.00M | 593.10M | 4.1873 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.89 | 56.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
127.42 | 55.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.98 | 48.36B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.69 | 40.01B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.36 | 20.62B | 3.13B | 1.27B | 1.12B | 26.39 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine’s Next VMAT2 Study Adds Depth To Tardive Dyskinesia Story - Yahoo Finance
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial - Yahoo Finance
Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation - simplywall.st
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
Will Neurocrine Biosciences Inc. stock pay special dividendsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Mediolanum International Funds Ltd Sells 15,811 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday - MarketBeat
Trading the Move, Not the Narrative: (NBIX) Edition - Stock Traders Daily
Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 13.9% - MarketBeat
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 31.99% Upside Potential for Investors - DirectorsTalk Interviews
Bank of New York Mellon Corp Has $106.89 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Thrivent Financial for Lutherans Sells 215,514 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Atle Fund Management AB Has $14.41 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update - simplywall.st
Y Intercept Hong Kong Ltd Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup - Chartmill
AlphaQuest LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Stifel reiterates Buy rating on Neurocrine Bio stock ahead of Q4 results - Investing.com Canada
Summit Global Investments Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
21,000 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Hussman Strategic Advisors Inc. - MarketBeat
Does Neurocrine Biosciences (NBIX) Price Weakness Signal A Long Term Opportunity? - simplywall.st
Is Neurocrine Biosciences (NBIX) Offering Value After Recent Share Price Weakness - Yahoo Finance
Assessing Neurocrine Biosciences (NBIX) Valuation After New Phase 2 VMAT2 Tardive Dyskinesia Trial Launch - Yahoo Finance
Higher VMAT2 Target Occupancy Observed in Valbenazine Over Deutetrabenazine Extended-Release Capsules - NeurologyLive
Neurocrine initiates phase 2 study for tardive dyskinesia treatment By Investing.com - Investing.com Nigeria
Neurocrine Biosciences begins Phase II NBI-1065890 trial for TD - Clinical Trials Arena
Neurocrine Biosciences, Inc. (NBIX): Investor Outlook On A 31.63% Potential Upside - DirectorsTalk Interviews
Gainers Report: What is Neurocrine Biosciences Inc.’s TAM (Total Addressable Market)2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - marketscreener.com
Neurocrine initiates phase 2 study for tardive dyskinesia treatment - Investing.com
Neurocrine Biosciences, Inc. $NBIX Holdings Lifted by Wealth Enhancement Advisory Services LLC - MarketBeat
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PR Newswire
New INGREZZA VMAT2 Data vs AUSTEDO XR Might Change The Case For Investing In Neurocrine (NBIX) - simplywall.st
Volume Report: How cyclical is Neurocrine Biosciences Incs revenue stream2025 Volume Leaders & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
(NBIX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Assessing Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Clinical Data And Pipeline Updates - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $178.00 at UBS Group - MarketBeat
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $178 - 富途牛牛
UBS Adjusts Price Target on Neurocrine Biosciences to $178 From $188, Maintains Buy Rating - marketscreener.com
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock - Chartmill
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Recap Report: Why is Neurocrine Biosciences Inc stock going up2025 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - The AI Journal
Neurocrine sets Feb. 11 webcast for Q4 and 2025 year-end financial results - Stock Titan
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BENEVICH ERIC | Chief Commercial Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,294 |
0 |
54,047 |
| ABERNETHY MATT | Chief Financial Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,437 |
0 |
38,465 |
| Cooke Julie | Chief Human Resources Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
1,741 |
0 |
28,599 |
| Delaet Ingrid | Chief Regulatory Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
801 |
0 |
5,531 |
| Gano Kyle | Chief Executive Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,927 |
0 |
143,334 |
| GORMAN KEVIN CHARLES | Director |
Jan 31 '26 |
Option Exercise |
0.00 |
5,142 |
0 |
519,738 |
| Lippoldt Darin | Chief Legal Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,373 |
0 |
49,127 |
| Onyia Jude | Chief Scientific Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
238 |
0 |
16,119 |
| Gano Kyle | Chief Executive Officer |
Jan 16 '26 |
Option Exercise |
35.99 |
36,400 |
1,310,036 |
174,995 |
| Gano Kyle | Chief Executive Officer |
Jan 16 '26 |
Sale |
132.70 |
36,400 |
4,830,458 |
140,407 |
8.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):